Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

Nature medicine - 1 Mar 2016

Ambrogio Chiara, Gómez-López Gonzalo, Falcone Mattia, Vidal August, Nadal Ernest, Crosetto Nicola, Blasco Rafael B, Fernández-Marcos Pablo J, Sánchez-Céspedes Montserrat, Ren Xiaomei, Wang Zhen, Ding Ke, Hidalgo Manuel, Serrano Manuel, Villanueva Alberto, Santamaría David, Barbacid Mariano

Abstract excerpt

Patients with advanced Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant lung adenocarcinoma are currently treated with standard chemotherapy because of a lack of efficacious targeted therapies. We reasoned that the identification of mediators of Kras signaling in early mouse lung hyperplasias might bypass the difficulties that are imposed by intratumor heterogeneity in advanced tumors, and that it might...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Dasatinib

Share to Neoplasm Transplantation

Share to Neoplasms, Experimental

Share to Paclitaxel

Share to Receptors, Notch

Source

Identifiers

PMID: 26855149
DOI: 10.1038/nm.4041

Genes

DDR1
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.PMID 26855149Read ↗

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilitiesSemantic proximity Read ↗

Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung AdenocarcinomaSemantic proximity Read ↗

Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.Semantic proximity Read ↗

Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.Semantic proximity Read ↗

Transcriptome Analysis of Individual Stromal Cell Populations Identifies Stroma-Tumor Crosstalk in Mouse Lung Cancer ModelSemantic proximity Read ↗

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.Semantic proximity Read ↗

A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung CancerSemantic proximity Read ↗

Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma.Semantic proximity Read ↗

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.Semantic proximity Read ↗

Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.Semantic proximity Read ↗

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.Semantic proximity Read ↗

ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.